ライフサイエンスコーパス: topoisomerase II inhibitor

1 vative, XWL-1-48, was synthesized as an oral topoisomerase II inhibitor.

2 (waf1) induction in response to etoposide, a topoisomerase II inhibitor.

3 calate into DNA double strands and is also a topoisomerase II inhibitor.

4 th DNA-damaging agents such as alkylators or topoisomerase II inhibitors.

5 n tumor cell line intrinsically resistant to topoisomerase II inhibitors.

6 the MLL gene are associated with the use of topoisomerase II inhibitors.

7 cer treatment at low cumulative doses of DNA topoisomerase II inhibitors.

8 ication of primary cancer treatment with DNA topoisomerase II inhibitors.

9 eukemia who previously were treated with DNA topoisomerase II inhibitors.

10 e specifically to mitoxantrone, not to other topoisomerase II inhibitors.

11 ion of exposure to natural and synthetic DNA topoisomerase II inhibitors.

12 susceptible to breakage in cells exposed to topoisomerase II inhibitors.

13 thesized dual-acting histone deacetylase and topoisomerase II inhibitors.

14 ive to double-strand DNA cleavage induced by topoisomerase II inhibitors.

15 g chemotherapy with alkylating agents and/or topoisomerase II inhibitors.

16 with chemotherapeutic regimens incorporating topoisomerase II inhibitors.

17 tion that they are induced by treatment with topoisomerase II inhibitors.

18 Prior therapy in this patient included DNA topoisomerase II inhibitors, alkylating agents, and irra

19 ere treated with various combinations of DNA topoisomerase II inhibitors, alkylating agents, or irrad

20 Topoisomerase II inhibitors also cooperated with Ad-E2F-

21 ly found that GPX is induced by etoposide, a topoisomerase II inhibitor and a p53 activator.

22 Topoisomerase II inhibitors and alkylators can induce t-

23 , and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methot

24 e the mid-1980s, when the intensified use of topoisomerase-II inhibitors and alkylators first gained

25 alkylating agent, the 27 who had received a topoisomerase II inhibitor, and the 37 who had received

26 kylating agents, DNA topoisomerase I and DNA topoisomerase II inhibitors, and local radiation.

27 hylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamin

28 Topoisomerase II inhibitors are widely used to treat hum

29 with alkylating agents, platinum analogs and topoisomerase II inhibitors, as well as the additive int

30 gp-170 P-glycoprotein, and one resistant to topoisomerase II inhibitors, CEM-VM1-5, which has a muta

31 zed with both doxorubicin and etoposide, two topoisomerase II inhibitors commonly used in SCLC chemot

32 role in effecting G(2) arrest in response to topoisomerase II inhibitors, depending upon the mechanis

33 ing that the bisdioxopiperazine class of DNA topoisomerase II inhibitors directly interacts with the

34 F-7 cells renders the cells sensitive to the topoisomerase II inhibitor doxorubicin (Doxo).

35 ession and enhanced chemosensitivity towards topoisomerase II inhibitor, doxorubicin, in breast cance

36 apy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause

37 has a cytotoxicity-protective effect against topoisomerase II inhibitor/E2F-1-induced apoptosis and s

38 be induced in mouse cells by exposure to the topoisomerase II inhibitor etoposide and is mediated in

39 our different epithelial cell lines with the topoisomerase II inhibitor etoposide in combination with

40 The topoisomerase II inhibitor etoposide induced p53-depende

41 Treatment of L929 fibroblasts by the topoisomerase II inhibitor etoposide killed 50% of the c

42 The cytotoxicity of the topoisomerase II inhibitor etoposide was also potentiate

43 rt here that during apoptosis induced by the topoisomerase II inhibitor etoposide, a fraction of GRP9

44 ted apoptosis-inducing ligand (TRAIL) or the topoisomerase II inhibitor etoposide, which damages DNA.

45 avage induced by a lower dose (5 muM) of the topoisomerase II inhibitor etoposide.

46 causes the development of resistance to the topoisomerase II inhibitor etoposide.

47 ificantly suppress apoptosis mediated by the topoisomerase II inhibitor etoposide.

48 to apoptosis when they were treated with the topoisomerase II inhibitor etoposide.

49 ificantly enhances cell death induced by the topoisomerase II inhibitors etoposide and doxorubicin an

50 h this property, treatment of cells with the topoisomerase-II inhibitor etoposide promotes chromosoma

51 ced by chemotherapeutic drugs, including the topoisomerase II inhibitor, etoposide.

52 higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin,

53 and then exposed to Adriamycin (ADR), a DNA topoisomerase II inhibitor, exhibit an altered pattern o

54 Thus, XWL-1-48 may be a promising orally topoisomerase II inhibitor for treatment of HCC.

55 ophenoxazine compounds has been developed as topoisomerase II inhibitors for anticancer chemotherapy.

56 ure to doxorubicin, a DNA-damaging agent and topoisomerase II inhibitor frequently used in cancer the

57 -OH ellipticine and cross-resistant to other topoisomerase II inhibitors has previously been shown to

58 emotherapy regimens for WT consist mainly of topoisomerase II inhibitors (i.e., actinomycin D, doxoru

59 ation could be prevented by treatment with a topoisomerase II inhibitor ICRF-193, suggesting that the

60 system to test whether aclacinomycin A is a topoisomerase II inhibitor in vivo and to test whether w

61 increased resistance to topoisomerase I and topoisomerase II inhibitors in a variety of human cell l

62 hibit NF-kappa B may enhance the efficacy of topoisomerase II inhibitors in clinical cancer chemother

63 rapy in three cases and prior treatment with topoisomerase-II inhibitors in two.

64 echanisms by which cleavable complex-forming topoisomerase II inhibitors interfere with DNA replicati

65 igh-dose use of alkylating agents given with topoisomerase-II inhibitors is strongly leukemogenic, ev

66 toposide, a widely used antitumor drug and a topoisomerase II inhibitor, is a prototypical inducer of

67 Diverse pro-apoptotic drugs, including topoisomerase II inhibitors, kinase inhibitors, and prot

68 arrest induced by cleavable complex-forming topoisomerase II inhibitors leads to the generation of i

69 cific cleavage within the MLL bcr induced by topoisomerase II inhibitors may be an early step leading

70 e high-dose cyclophosphamide, cisplatin, and topoisomerase-II inhibitors may entail a considerable ri

71 706744) and NSC 724998, but sensitive to the topoisomerase II inhibitors mitoxantrone and etoposide.

72 These secondary leukemias associated with topoisomerase II inhibitors (most commonly teniposide, e

73 DNA lesions generated by etoposide, a DNA topoisomerase II inhibitor, or by exonuclease treatment

74 hesis and biological evaluation of novel DNA topoisomerase II inhibitors, podophenazine (8), 2'',3''

75 Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been s

76 reakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a conseq

77 a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in

78 ated stress protein (GRP78) are resistant to topoisomerase II inhibitors, such as etoposide, m-amsacr

79 e induced by chemotherapeutic agents such as topoisomerase-II inhibitors suggest that apoptogenic age

80 Ionizing radiation and the topoisomerase II inhibitor, teniposide (VM-26) both incr

81 Prior therapy included the DNA topoisomerase II inhibitors, teniposide and doxorubicin.

82 F-1-expressing cells with ICRF-193, a second topoisomerase II inhibitor that does not damage DNA, pro

83 LU-79553 is a DNA-binding topoisomerase II inhibitor that is particularly effectiv

84 We have previously reported on a family of topoisomerase II inhibitors that also interact with G-qu

85 s of the antibacterial fluoroquinolones, are topoisomerase II inhibitors that have demonstrated promi

86 Bisdioxopiperazines are a unique class of topoisomerase II inhibitors that lock topoisomerase II a

87 y twelve topoisomerase I inhibitors and four topoisomerase II inhibitors that unsilence the paternal

88 At the first detection of MLL-ENL, the only topoisomerase II inhibitors the patient had received wer

89 th topoisomerase I poison trials, ifosfamide/topoisomerase II inhibitor trials had superior FFS (P =

90 ases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing

91 genomic fusions can occur after exposure to topoisomerase II inhibitors, we developed a long-distanc

92 n (topoisomerase I inhibitor) or adriamycin (topoisomerase II inhibitor) were not equivalent.

93 protect RCE and PRCE cells from etoposide, a topoisomerase II inhibitor, which induced cell death by

94 Etoposide, a topoisomerase II inhibitor widely used in cancer therapy

95 DRZ is a topoisomerase II inhibitor with a mechanism distinct fro

96 and 25 were "cleavable-complex"-forming DNA topoisomerase II inhibitors with either improved or simi